Back to search

Article

Impact of KRAS mutations on clinical outcomes of patients with advanced non-squamous non-small cell lung cancer receiving anti PD1/PDL1 therapy.

2022-03-10

Abstract excerpt

<title>Abstract</title> <p><bold>Purpose</bold>To evaluate the impact of KRAS mutations on response and survival outcomes in mutated vs wild type KRAS advanced non squamous non small cell lung cancer patients treated with immune checkpoint inhibitors alone or in combination with chemotherapy.<bold> </bold><bold>Patients and methods</bold>We retrospectively identified 119 patients, most of which (58%) were wild ty...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
64141c60-3bd5-58fa-9c1b-ba9a4f78be09
DOI
10.21203/rs.3.rs-1416356/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Impact of KRAS mutations on clinical outcomes of patients with advanced non-squamous non-small cell lung cancer receiving anti PD1/PDL1 therapy.DOI 10.21203/rs.3.rs-1416356/v1
Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy.Semantic proximity
A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.Semantic proximity
Prognostic Value of KRAS Mutations in Relation to PDL1 Expression and Immunotherapy Treatment in Adenocarcinoma and Squamous Cell Carcinoma Patients: A Greek Cohort StudySemantic proximity
Clinicopathological Characteristics and Prognostic Impact of KRAS Mutations in Non-Small Cell Lung Cancer.Semantic proximity
Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy.Semantic proximity
Clinical presentation and outcomes according to KRAS status in advanced non-small cell lung cancerSemantic proximity
Prognostic value of KRAS G12C in advanced non-small cell lung cancer with high PD-L1 expression treated with upfront immunotherapy: a systematic review and meta-analysis.Semantic proximity
<i>KRAS</i>mutations impact clinical outcome in metastatic non-small cell lung cancerSemantic proximity
Correlation between KRAS mutation subtypes and prognosis in Chinese advanced non-squamous non-small cell lung cancer patients.Semantic proximity
Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With ImmunotherapySemantic proximity
Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.Semantic proximity
The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience.Semantic proximity
Select a neighboring publication to make it the new centre.